Immunome Inc
IMNM
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.39B
Close$
$7.26
72.5% downside
Current Fair Value
72.5% downsideOvervalued by 72.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.39 Billion |
|---|---|
| Enterprise Value | $2.18 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.43 |
| Beta | 2.07 |
| Outstanding Shares | 113,136,836 |
Return
| Return on Equity | -48.43% |
|---|---|
| Return on Assets | -44.98% |
| Return on Invested Capital | -48.23% |
Valuation & Multiples
| P/E Ratio | -10.47 |
|---|---|
| PEG | -15.29 |
| Price to Sales | - |
| Price to Book Ratio | 6.61 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.53 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$166,667
Average shareholder expectationNext Earnings Call
Expected Date
August 19, 2026
EPS Estimate
$-0.59
Average shareholder expectationRevenue Estimate
$222,222
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 5.1033▲ 257.14% |
|---|---|
| Total Calls | 269,100▼ 71.11% |
| Total Puts | 1,373,300▼ 41.78% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 133.56%▼ 1.91% |
|---|---|
| Total Invested | $2.54B▲ 0.13% |
| Investors Holding | 207▲ 11.00% |
ESG Score
No data
About Immunome Inc
2,020 employeesImmunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initi...